Payment overview · 2025
General Payments
$744.87
45 reported records · 13 companies
Healthcare provider profile · identity verified
Sanjeev V Joshi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OLYMPIA FIELDS, IL · NPI 1962467563
Verified facts
What the public records show
CMS Open Payments records show Sanjeev V Joshi, M.D. received $744.87 in general payments during 2025 across 45 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.67 | 20.4% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $146.23 | 19.6% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.65 | 17.4% | 12 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $70.17 | 9.4% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $45.25 | 6.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.58 | 5.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.98 | 4.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $27.13 | 3.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.62 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.73 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.15 | 3.0% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $16.52 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.19 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $744.87 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.43 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $105.99 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.14 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.14 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $75.14 | 4 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $70.17 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.24 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $45.25 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
210 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
231 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1567 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 1112 | 233 |
| Gabapentin | Gabapentin | 790 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 709 | 134 |
| Eliquis | Apixaban | 621 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 575 | 104 |
| Metformin Hcl | Metformin Hcl | 559 | 120 |
| Furosemide | Furosemide | 536 | 93 |
| Lisinopril | Lisinopril | 534 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 521 | 91 |
| Donepezil Hcl | Donepezil Hcl | 514 | 63 |
| Potassium Chloride | Potassium Chloride | 460 | 68 |
| Losartan Potassium | Losartan Potassium | 443 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 423 | 87 |
| Omeprazole | Omeprazole | 387 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 365 | 68 |
| Meloxicam | Meloxicam | 335 | 62 |
| Simvastatin | Simvastatin | 332 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 318 | 117 |
| Sertraline Hcl | Sertraline Hcl | 317 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 67 |
| Glimepiride | Glimepiride | 294 | 67 |
| Alprazolam | Alprazolam | 265 | 62 |
| Trazodone Hcl | Trazodone Hcl | 264 | 49 |
| Carvedilol | Carvedilol | 251 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 240 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 233 | 60 |
| Jardiance | Empagliflozin | 231 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 227 | 55 |
| Memantine Hcl | Memantine Hcl | 220 | 28 |
| Myrbetriq | Mirabegron | 210 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 60 |
| Levetiracetam | Levetiracetam | 203 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 30 |
| Montelukast Sodium | Montelukast Sodium | 200 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 34 |
| Mirtazapine | Mirtazapine | 194 | 40 |
| Allopurinol | Allopurinol | 184 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 170 | 39 |
| Famotidine | Famotidine | 167 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 34 |
| Tramadol Hcl | Tramadol Hcl | 152 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 144 | 17 |
| Spironolactone | Spironolactone | 144 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 32 |
| Prednisone | Prednisone | 138 | 76 |
| Latanoprost | Latanoprost | 134 | 22 |
| Alendronate Sodium | Alendronate Sodium | 133 | 33 |
| Nifedipine Er | Nifedipine | 133 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 131 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 130 | 18 |
| Ozempic | Semaglutide | 128 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 36 |
| Finasteride | Finasteride | 117 | 31 |
| Lorazepam | Lorazepam | 111 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 100 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 98 | 22 |
| Buspirone Hcl | Buspirone Hcl | 93 | suppressed |
| Ibuprofen | Ibuprofen | 93 | 26 |
| Xarelto | Rivaroxaban | 89 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 41 |
| Glipizide | Glipizide | 75 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 21 |
| Celecoxib | Celecoxib | 73 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 18 |
| Olanzapine | Olanzapine | 67 | suppressed |
| Aripiprazole | Aripiprazole | 64 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 15 |
| Clonazepam | Clonazepam | 64 | 19 |
| Levofloxacin | Levofloxacin | 63 | 51 |
| Hydrocortisone | Hydrocortisone | 62 | suppressed |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Baclofen | Baclofen | 59 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 57 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Diazepam | Diazepam | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 55 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 52 |
| Lovastatin | Lovastatin | 54 | 11 |
| Warfarin Sodium | Warfarin Sodium | 54 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 13 |
| Gemtesa | Vibegron | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 53 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 15 |
| Azithromycin | Azithromycin | 48 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 13 |
| Pregabalin | Pregabalin | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 13 |
| Estradiol | Estradiol | 43 | suppressed |
| Risperidone | Risperidone | 43 | suppressed |
| Colchicine | Colchicine | 42 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 16 |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Naproxen | Naproxen | 42 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 41 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 41 | suppressed |
| Cephalexin | Cephalexin | 41 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 11 |
| Mometasone Furoate | Mometasone Furoate | 41 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 15 |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Glipizide Er | Glipizide | 36 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Mirabegron Er | Mirabegron | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Verapamil Sr | Verapamil Hcl | 29 | suppressed |
| Phenytoin | Phenytoin | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Trospium Chloride | Trospium Chloride | 27 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Nystatin | Nystatin | 25 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Constulose | Lactulose | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Rhopressa | Netarsudil Mesylate | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Calcitriol | Calcitriol | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $744.87 · 45 records | ABBVIE INC. | APRETUDE, GEMTESA, IBSRELA, Kerendia, MOUNJARO, NEFFY, Ozempic, QULIPTA, REXULTI, Rybelsus, Tymlos, UBRELVY, VRAYLAR, Veozah, Wegovy, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error